trial fibrillation (AF) is associated with higher thromboembolic risk, possibly because of the hypercoagulable state. 1,2 Elevated levels of hemostatic markers have been shown in patients with nonrheumatic AF. [2][3][4][5][6] During AF, stagnation of blood flow in the left atrial appendage (LAA) could contribute to the hypercoagulable state and clot formation in the fibrillating atria. Hemostatic markers could be therefore used for stratification of patients at high risk vs low risk for thromboembolism as demonstrated in previous studies. [1][2][3][4][5][6] Aortic atheroma is recognized as an important marker of stroke and peripheral embolism in patients with AF. 7-9 The SPAF-III investigators reported that complex aortic plaque emerged as a risk factor of thromboembolism in patients with nonrheumatic AF, and warfarin was effective in reducing stroke in patients with AF and complex aortic plaque. 10 Complex aortic plaques with ulcerated or mobile plaques and superimposed thrombi would activate hemostatic markers. The Framingham Offspring Study raised the possibility that the increases in hemostatic factors in patients with AF were mainly caused by the confounding effect of traditional risk factors and coexistent cardiovascular diseases rather than by AF itself. 2 We recently reported that patients with nonrheumatic AF had elevated levels of D-dimer when complicated with spontaneous echocardiographic contrast (SEC) in the descending thoracic aorta. 11Because AF and aortic atherosclerosis might contribute synergistically to increased levels of hemostatic markers, and could be associated with increased risk of thromboembolism, we determined the relationship between plasma levels of hemostatic markers and atherosclerosis in the descending thoracic aorta assessed by transesophageal echocardiography (TEE) in patients with nonrheumatic AF and in those in sinus rhythm (SR).
Methods
Study PatientsEchocardiographic and hematologic studies were performed in 106 consecutive patients (79 men, 27 women; mean age of 67±11 years) referred to a university hospital for cardiovascular assessment for stroke risk or identification of the cardiogenic source of recent embolism. Patients who received anticoagulant therapy were not included in the present study. Of these 106 patients, AF was documented electrocardiographically in 60 patients (AF group) but not in the remaining 46 patients (SR group). The study protocol was approved by the institutional ethics committee and written informed consent was given by all patients. Underlying heart diseases included the following: ischemic heart disease (n=8), hypertrophic cardiomyopathy (n=4), dilated cardiomyopathy (n=5), sick sinus syndrome (n=3), atrial septal defect (n=5), post pericarditis (n=6), and miscellaneous diseases (n=20). No apparent underlying diseases were identified in 55 patients. Baseline clinical characteristics, including body mass index, diabetes mellitus, hyperlipidemia, smoking, previous cerebral or peripheral embolic event and the use of oral antiplatelet medication at...